Advertisement

Hämostasestörungen bei chronischer Leberschädigung

  • A. Jedrychowski

Zusammenfassung

Die Leber spielt eine Schlüsselrolle in der Regulation der Blutstillung. Sie ist der Bildungsort fast aller Gerinnungsfaktoren sowie von Gerinnungs- und Fibrolyseinhibitoren, sie entfernt aus dem Kreislauf aktivierte Hämostaseprodukte, und nicht zuletzt trägt sie wesentlich zur Thrombozytenfunktion und Integrität der kleinen Blutgefäße bei. Dies erklärt, warum die Erkrankungen der Leber oft mit komplexen Hämostasestörungen einhergehen und nicht selten durch lebensbedrohliche Blutungen kompliziert werden. Es ist auch verständlich, daß eine rationelle Prophylaxe sowie Therapie der hämorrhagischen Komplikationen bei Leberkranken nur aufgrund von Kenntnissen der physiologischen Rolle der Leber bei der Hämostaseregulation möglich ist.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Abildgaard CHF (1981) Hazards of prothrombin-complex concentrates in treatment of hemophilia. N Engl J Med 304: 670PubMedGoogle Scholar
  2. 2.
    Ahtee L, Briley M, Raisman R, Lebrec D, Langer SZ (1981) Reduced uptake of serotonin but unchanged 3H-imipramine binding in the platelets from cirrhotic patients. Life Sci 29: 2323–2329PubMedGoogle Scholar
  3. 3.
    Aoki N, Moroi N, Matsuda M, Tachiya K (1977) The behaviour of alpha2-Plasmin inhibitor in fibrinolytic states. J Clin Invest 60: 361–369PubMedGoogle Scholar
  4. 4.
    Aoki N, Yamanaka T (1978) The alpha2-plasmin inhibitor levels in liver diseases. Clin Chim Acta 84: 99–105PubMedGoogle Scholar
  5. 5.
    Aster R (1966) Pooling of platelets in the spleen: role in the pathogenesis of “hyper- splenic” thrombocytopenia. J Clin Invest 45: 645–657PubMedGoogle Scholar
  6. 6.
    Astrup T, Rasmussen J, Amery A, Poulsen HE (1960) Fibrinolytic activity of cirrhotic liver. Nature 185: 619–620PubMedGoogle Scholar
  7. 7.
    Audhuy B, Doffoel M, Wiesel ML, Hemmendinger S, Cazenave JP, Bockel R (1983) Importance des troubles de l’hemostase primaire dans la survenue des hemorrhagies digestives hautes du cirrhotique. Ann Gastroenterol Hepatol (Paris) 20: 177–182Google Scholar
  8. 8.
    Aurousseau MH, d’Angeli GD, Josso F (1981) Antithrombin III versus prothrombin in liver cirrhosis. Haemostasis 10: 104–107PubMedGoogle Scholar
  9. 9.
    Ballard H, Aaron J (1976) Platelet aggregation in portal cirrhosis. Arch Intern Med 136: 316–319PubMedGoogle Scholar
  10. 10.
    Bartaglia E, Belmonte P, Vertolli U, Azzurro M, Martines D (1983) Bleeding in cirrhotic patients: a precipitating factor due to intravascular coagulation or to hepatic failure? Haemostasis 13: 328–334Google Scholar
  11. 11.
    Bechthold H, Andrassy K, Koderisch H, Weilemann LS, Sonntag HG, Ritz E (1984) Evidence for impaired hepatic vitamin Ki metabolism in patients treated with N- methyl-thiotetrazole cephalosporins. Thromb Haemost 51: 358–361Google Scholar
  12. 12.
    Bergström K, Blombäck B, Kleen G (1960) Studies on the plasma fibrinolytic activity in a case of liver cirrhosis. Acta Med Scand 168: 291–305Google Scholar
  13. 13.
    Biland L, Duckert F, Prisender S, Nymann D (1978) Quantitative estimation of coag–ulation factors in liver disease. The diagnostic and prognostic value of factor XIII, factor V and plasminogen. Thromb Haemost 39: 646–656Google Scholar
  14. 14.
    Blanchard RA, Furie BC, Jörgensen M, Gruger SF, Furie B (1981) Acquired vitamin K - dependent carboxylation deficiency in liver disease. N Engl J Med 305: 242–248PubMedGoogle Scholar
  15. 15.
    Blatt PM, Lundbald RL, Kingdon HS, McLean G, Roberts MK (1974) Thrombogenic materials in prothrombin complex concentrates. Ann Intern Med 81: 766–770PubMedGoogle Scholar
  16. 16.
    Blatt PM, White GC, Kingdon HS (1981) Use of prothrombin complex concentrates in acquired coagulopathies. In: Lusher JM, Barnhart MJ (eds) Acquired bleeding disorders in children. Abnormalities of hemostasis. Masson, New York, p 127Google Scholar
  17. 17.
    Blauhut B, Necek S, Vinazzer H, Bergmann H (1982) Substitution therapy with an antithrombin Ill-concentrate in shock and DIC. Thromb Res 27: 271–278PubMedGoogle Scholar
  18. 18.
    Bloom AL (1975) Annotation; intravascular coagulation and the liver. Br J Haematol 30: 1–7PubMedGoogle Scholar
  19. 19.
    Bloom AL (1981) Pathogenesis of haemostatic abnormalities in liver disease. In: Bloom AL, Thomas DP (eds) Haemostasis and thrombosis. Churchill Livingstone, Edinburgh, pp 422–427Google Scholar
  20. 20.
    Boks AL, Brommer EJP, Solko W, Schalm W, van Vliet HDM (1986) Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage. Hepatology 6: 79–86PubMedGoogle Scholar
  21. 21.
    Booth N, Anderson JA, Bennett B (1984) Plasminogen activators in alcoholic cirrhosis: demonstration of increased tissue type and urokinase type activator. J Clin Pathol 37: 772–777PubMedGoogle Scholar
  22. 22.
    Boyett JD, Sullivan JF, Rocca RCD (1970) Hyperfibrinolysis in cirrhosis. NeBr Med J 55: 230–236PubMedGoogle Scholar
  23. 23.
    Breddin K (1962) Hämorrhagische Diathesen bei Lebererkrankungen unter besonderer Berücksichtigung der Thrombozytenfunktion. Acta Haematol 27: 1–16PubMedGoogle Scholar
  24. 24.
    Brodsky J, Siegel NH, Kahn SB, Roos EM, Petkov C (1970) Simultaneous fibrinogen and platelet survival with (75Se) Selenomehtionine in man. ( Studies in diseases with normal coagulation and in hepatocellular disease with abnormal coagulation ). Br J Haematol 18: 341–355PubMedGoogle Scholar
  25. 25.
    Büller HR, Hobbelen MJ, Princeen AWN, Moelker HCT, ten Cate JW (1983) The effects of antithrombin III, heparin and a novel heparinoid infusions on the bleeding tendency using an experimental model in the rat. Thromb Res 31: 787–797PubMedGoogle Scholar
  26. 26.
    Burri HP (1984) Frisch gefrorenes Plasma (FGP) Indikation und Anwendung. Ther Umsch 41: 560–564PubMedGoogle Scholar
  27. 27.
    Cederblad C, Korsan-Bengtsen K, Olsson R (1976) Observations of increased levels of Blood coagulation factors and other plasma proteins in cholestatic liver disease. Scand J Gastroenterol 11: 391–396PubMedGoogle Scholar
  28. 28.
    Coccheri S, Gasbarrini G (1973) The relevance of Blood clotting tests in chronic aggressive hepatitis. Scand J Gastroenterol 8 [Suppl 19]: 97–101Google Scholar
  29. 29.
    Coccheri S, Palareti G, Dalmonte PR, Poggi M, Boggian O (1979) Investigations on intravascular coagulation in liver disease: soluble fibrin monomer complexes in liver cirrhosis. Haemostasis 8: 8–18PubMedGoogle Scholar
  30. 30.
    Collen D (1984) Intravascular coagulation in liver disease. In: Fondu P, Thijs O (eds) Haemostatic failure in liver disease. Nijhoff, Boston, pp 44–48Google Scholar
  31. 31.
    Collen D, Rouvier J, Verstraete M (1972) Metabolism of iodine-labelled plasminogen and prothrombin in cirrhosis of the liver. Clin Res 20: 483 (Abstract)Google Scholar
  32. 32.
    Collen D, Rouvier J, Chamone DAF, Verstraete M (1978) Turnover of radiolabeled plasminogen and prothrombin in cirrhosis of the liver. Eur J Clin Invest 8: 185–199PubMedGoogle Scholar
  33. 33.
    Cordova C, Musca A, Violi F, Alessandri C, Vezza E (1982) Improvement of some Blood coagulation factors in cirrhotic patients treated with low doses of heparin. Scand J Haematol 29: 235–240PubMedGoogle Scholar
  34. 34.
    Corrigan JJ, Jeter M, Earnest DL (1982) Prothrombin antigen and coagulant activity in patients with liver disease. JAMA 248: 1736–1739PubMedGoogle Scholar
  35. 35.
    Cowan D (1973) Thrombokinetic studies in alcohol-related thrombocytopenia. J Lab Clin Med 81: 64–76PubMedGoogle Scholar
  36. 36.
    Damus PS, Wallace GA (1975) Immunologie measurement of antithrombin III-heparin cofactor and alpha2-macroglobulin in disseminated intravascular coagulation and hepatic failure coagulopathy. Thromb Res 6: 27–38PubMedGoogle Scholar
  37. 37.
    Das PC, Cash JD (1969) Fibrinolysis at rest and after exercise in hepatic cirrhosis. Br J Haematol 17: 431–443PubMedGoogle Scholar
  38. 38.
    Denk H, Schmack H, Deutsch E (1970) Histochemical detection of fibrinolytic activity in liver biopsies. Acta Hepatosplenol 17: 221–228PubMedGoogle Scholar
  39. 39.
    Deutsch E (1965) Blood coagulation changes in liver diseases. In: Popper H, Schaffner F (eds) Progress in liver diseases, vol 2. Grune & Stratton, New York, pp 69–93Google Scholar
  40. 40.
    Deykin D (1966) The role of the liver in serum induced hypercoagulability. J Clin Invest 45: 256–263PubMedGoogle Scholar
  41. 41.
    Dioguardi N, Mari D, Ninno E del, Mannucci PM (1973) Fibrinolysis in cholestatic jaundice. Br Med J 2: 778–779PubMedGoogle Scholar
  42. 42.
    Donaldson G, Davies S, Darg A, Richmond J (1969) Coagulation factors in chronic liver disease. J Clin Pathol 22: 199–204PubMedGoogle Scholar
  43. 43.
    Duckert F (1973) Behaviour of antithrombin III in liver disease. Scand J Gastroenterol 8 [Suppl 19]: 109–112Google Scholar
  44. 44.
    Emeis JJ, van den Hoogen CM, Jense D (1985) Hepatic clearance of tissue type plasminogen activator in rats. Thromb Haemost 54: 661–664PubMedGoogle Scholar
  45. 45.
    Ewe K (1981) Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Dig Dis Sci 26: 388–393PubMedGoogle Scholar
  46. 46.
    Fischer M, Falkensammar C, Klein HJ, Irsigler K, Brunder H, Schnack H (1976) Therapeutische Möglichkeiten bei Verbrauchskoagulopathien aktiver Leberzirrhosen: niederdosierte Heparintherapie. Wien Klin Wochenschr 88: 488–494PubMedGoogle Scholar
  47. 47.
    Fletcher AP, Biederman O, Moore D, Alkjaersig N, Sherry S (1964) Abnormal plasmi- nogen-plasmin system activity (fibrinolysis) in patients with hepatic cirrhosis: its cause and consequences. J Clin Invest 43: 681–695PubMedGoogle Scholar
  48. 48.
    Flute PT (1979) Clotting abnormalities in liver disease. In: Popper H, Schaffner F (eds) Progres in liver disease, vol VI. Grune & Stratton, New York, pp 301–312Google Scholar
  49. 49.
    Foreman WB, Barnhart MJ (1964) Cellular site for fibrinogen synthesis. JAMA 184: 128–132Google Scholar
  50. 50.
    Francis JL, Armstrong DJ (1982) Acquired dysfibrinogenaemia in liver disease. J Clin Pathol 35: 667–672PubMedGoogle Scholar
  51. 51.
    Francis JL, Sommonds VL, Armstrong DJ (1983) fibrinogenbound sialic acid and liver sialyltransferase activity in an experimental animal model of cirrhosis. Thromb Haemost 50: 202Google Scholar
  52. 52.
    Francis RB, Thomas W (1984) Behaviour of protein C inhibitor in intravascular coagulation and liver disease. Thromb Haemost 52: 71–74PubMedGoogle Scholar
  53. 52a.
    Francis RB, Feinstein DJ (1984) Clinical significance of accelerated fibrinolysis in liver disease. Haemostasis 14: 460–465PubMedGoogle Scholar
  54. 53.
    Franco D, Deporte A, Durandy Y, Bismuth H (1977) Upper gastrointestinal haemorrhage in hepatic-cirrhosis: causes to hepatic failure and stress. Lancet 1: 218–220PubMedGoogle Scholar
  55. 54.
    Frick W (1967) Thrombozytopenie und Leberzirrhose. Schweiz Med Wochenschr 97: 407–413PubMedGoogle Scholar
  56. 55.
    Gans H, Lowman JT (1967) The uptake of fibrin and fibrin-degradation products by the isolated perfused rat liver. Blood 29: 526–539PubMedGoogle Scholar
  57. 56.
    Gazzard BG, Lewis ML, Ash G, Rizza CR, Bidwell E, Williams R (1974) Coagulation factor concentrates in the treatment of haemorrhagic diathesis of fulminant hepatic failure. Gut 15: 993–998PubMedGoogle Scholar
  58. 57.
    Gehrmann G, Elbers C (1970) Thrombopenisches Hyperspleniesyndrom bei spleno– megaler Leberzirrhose. Dtsch Med Wochenschr 27: 1429–1432Google Scholar
  59. 58.
    Ghezzo F, Mazzone R, Romano S, Emanueli G (1986) Increased whole Blood fibrinolytic activity in cirrhotic patients. Thromb Haemost 55: 147PubMedGoogle Scholar
  60. 59.
    Giddings JC (1984) Coagulation factors synthesis by the liver, with special reference to factor VIII and factor V. In: Fondu P, Thijs O (eds) Haemostatic failure in liver disease. Nijhoff, Boston, pp 5–22Google Scholar
  61. 60.
    Girolami A, Padrasti G, Capellato G, Quaino V (1980) An immunological study of prothrombin in liver cirrhosis. Blut 41: 61–66PubMedGoogle Scholar
  62. 61.
    Green G, Thomson JM, Dymock JW, Poller L (1976) Abnormal fibrin polymerization in liver disease. Br J Haematol 34: 427–439PubMedGoogle Scholar
  63. 62.
    Greig PD, Langer B, Blendis LM, Taylor BR, Glyn MFX (1980) Complications after peritoneovenous shunting for ascites. Am J Surg 139: 125–131PubMedGoogle Scholar
  64. 63.
    Griffin JA, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C (1981) Deficiency of protein C in congenital thrombotic disease. J Clin Invest 68: 1370–1373PubMedGoogle Scholar
  65. 64.
    Grossi D, Rousselot L, Panke W (1962) Coagulation defects in patients with cirrhosis of the liver undergoing portasystemic shunt. Am J Surg 104: 512–526PubMedGoogle Scholar
  66. 65.
    Haanen C (1973) Coagulation and liver disease (General discussion). Proc Symp Coag- ul Liver Dis. Scand J Gastroenterol 8 [Suppl 19]: 161Google Scholar
  67. 66.
    Hadchouel P, Touboul JP, Caroli J (1973) Study on the correlation between Normotest, Quick’s method and specific coagulation factors in liver disease. Scand J Gastroenterol 8 [Suppl 19]: 151–154Google Scholar
  68. 67.
    Harenberg J, Hepp G, Schmidt-Gayk H (1979) Fibrinopeptide A in human plasma evaluation of a new radioimmune-assay technique on microliter plates. Thromb Res 15: 513–522PubMedGoogle Scholar
  69. 68.
    Harmon DC, Demirijan Z, Ellman L, Fischer JE (1979) Disseminated intravascular coagulation with the peritoneovenous shunt. Ann Intern Med 90: 774–776PubMedGoogle Scholar
  70. 69.
    Heene DL (1973) Leber und Blutstillung. Therapeutische Probleme. Thromb Diathes Haemorrh [Suppl] 55: 145–151Google Scholar
  71. 70.
    Heene DL (1975) Gerinnungsstörung bei portaler Hypertension. Z Gastroenterol 13: 147–157Google Scholar
  72. 71.
    Heene DL (1979) Hämostasestörungen bei Lebererkrankungen. In: Kühn HA, Wernze H (Hrsg) Klinische Hepatologie. Thieme, Stuttgart, S 3.105–3. 119Google Scholar
  73. 72.
    Hillenbrand P, Parbhoo SP, Jedrychowski A, Sherlock S (1974) Significance of in-travascular coagulation and fibrinolysis in acute hepatic failure. Gut 15: 83–88PubMedGoogle Scholar
  74. 73.
    Hiller E, Hegemann F, Possinger K (1981) Hypercoagulability in acute oesophageal variceal bleeding. Thromb Res 22: 243–251PubMedGoogle Scholar
  75. 74.
    Hiller E, Riess H (1985) Klinische Bedeutung der Gerinnungsinhibitoren Antithrombin III und Protein C. Therapiewoche 35: 1533–1541Google Scholar
  76. 75.
    Höcker P (1980) Granulozyten- und Thrombozytensubstitution. Infusionstherapie 4: 197–203Google Scholar
  77. 76.
    Hughes RD, Lane DA, Ireland H, Langley PG, Gimson AES, Williams R (1985) Fibrinogen derivatives and platelet activation products in acute and chronic liver disease. Clin Sci 68: 701–707PubMedGoogle Scholar
  78. 77.
    Jaffe EA, Hoyer LW, Nachman RL (1973) Synthesis of antihemophilic factor antigen by cultured human endothelial cells. J Clin Invest 52: 2757–2764PubMedGoogle Scholar
  79. 78.
    Januszko T, Furman M, Buluk K (1966) The kidneys and the liver as the organs regulating the fibrinolytic system of the circulating Blood. Thromb Diathes Haemorr 15: 554–560Google Scholar
  80. 79.
    Jedrychowski A (1974) The role of the liver in mechanisms regulating fibrinolytic activity. Folia Med Cracov 16: 153–191Google Scholar
  81. 80.
    Jedrychowski A, Hillenbrand P, Ajdukiewicz AB, Parbhoo SP, Sherlock S (1973) Fibrinolysis in cholestatic jauncide. Br Med J 1: 640–642PubMedGoogle Scholar
  82. 81.
    Jedrychowski A, Parbhoo SP, Hillenbrand P (1972) Plasminogen activator in bile during extracorporeal perfusion of pig liver. Gut 13: 54–57PubMedGoogle Scholar
  83. 82.
    Jedrycowski A, Parbhoo SP, Hillenbrand P (1972) Inhibition of fibrinolysis in extracor-poreal pig liver perfusion. Scand J Gastroenterol 7: 551–554Google Scholar
  84. 83.
    Kasper CK (1975) Thromboembolic complications. Thromb Diathes Haemorrh 33: 640–644Google Scholar
  85. 84.
    Kaulla KN von (1964) Liver in regulation of fibrinolytic activity. Lancet 1:1046– 1047Google Scholar
  86. 85.
    Kingdon HS, Lundblad RL, Veitkam JJ, Aronson DL (1975) Potentially thrombogenic materials in factor IX concentrates. Thromb Diathes Haemorrh 33: 617–631Google Scholar
  87. 86.
    Klingemann HG, Egbring R, Havemann K (1980) Structure of fibrin and fibrin monomer in renal and hepatic failure. Klin Wochenschr 58: 533–535PubMedGoogle Scholar
  88. 87.
    Knot EAR, Driyfhout HR, Kahle LH, ten Cate JW, Tijtgat GN (1984) Kinetic studies of radiolabeled alpha2-antiplasmin and antithrombin III simultaneously in patients with liver disease. Haemostasis 14 /1: 110Google Scholar
  89. 88.
    Röttgen E, Schölmerich J, Diemer W, Gerok W (1982) Untersuchungen zur Blu-tungsneigung bei Ascites-Reinfusion. Verh Dtsch Ges Inn Med 88: 1170–1173Google Scholar
  90. 89.
    Koj A (1974) Acute phase reactants - their synthesis, turnover and biological significance. In: Allison AL (ed) Structure and function of plasma proteins, vol 1. Plenum, London, pp 73–131Google Scholar
  91. 90.
    Koj A, Regoeczi E, Toews CJ, Leveille R, Gauldie J (1978) Synthesis of antithrombin III and alpha2-antitrypsin by the perfused rat liver. Biochim Biophys Acta 539:496– 504Google Scholar
  92. 91.
    Kupfer HG, Gee W, Ewald AT (1963) Statistical correlation of liver function tests with coagulation factor deficiences in Laennec’s cirrhosis. Thromb Diath Haemorrh 10: 317–331Google Scholar
  93. 92.
    Lahnborg G, Berghem L, Lagergren H, Schildt B (1976) Effect of low-dose heparin on the phagocytic and catabolic function of the reticuloendothelial system in man during surgery. Ann Chir Gynaecol 65: 376–381PubMedGoogle Scholar
  94. 93.
    Langley PG, Hughes RD, Williams R (1982) Platelet adhesiveness to glass beads in liver disease. Acta Haematol 67: 124–127PubMedGoogle Scholar
  95. 94.
    Larrieu MJ, Dray L, Ardaillou N (1975) Biological effects of fibrinogen fibrin degradation products. Thromb Diathes Haemorrh 34: 686–692Google Scholar
  96. 95.
    Lasch HG, Müller-Berghaus G (1980) Prokontra: Verbrauchskoagulopathie — Heparinbehandlung? Argumente für eine Heparinbehandlung. Internist 21: 382–384Google Scholar
  97. 96.
    Latallo ZS, Budzynski A, Lipinski B, Kowalski E (1964) Inhibition of thrombin and of fibrin polymerisation, two activities derived from plasmin-digested fibrinogen. Nature 203: 1184PubMedGoogle Scholar
  98. 97.
    Lechner K (1980) Rationelle Substitutionstherapie bei Gerinnungsstörungen. Infusionstherapie 7: 190–194Google Scholar
  99. 98.
    Lechner K, Niessner H, Thaler E (1977) Coagulation abnormalities in liver disease. Semin Thromb Hemost 4: 40–56PubMedGoogle Scholar
  100. 99.
    Leone G, Agostini A, Mango G, Landolfi R, Valori V, Bizzi B (1981) Megathrombocytes, platelet regeneration time and platelet associated IgG in idiopathic thrombocy-topenic purpura and in thrombocytopenia associated with chronic liver disease. Acta Haematol (Basel) 65: 40–47Google Scholar
  101. 100.
    Lewis JH (1950) Studies on a proteolytic enzyme system of the Blood. II. Fibrinolysokinase activators for Profibrinolysin. J Clin Invest 29: 1059–1068PubMedGoogle Scholar
  102. 101.
    Lewis JH, Doyle AP (1964) Effects of epsilon aminocaproic acid on coagulation and fibrinolytic mechanisms. JAMA 188: 56–63PubMedGoogle Scholar
  103. 102.
    Lipsky JJ (1983) N-Methyl-thiotetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanisms of antibiotic-associated hypoprothrombinemia. Lancet 11: 192–193Google Scholar
  104. 103.
    Van de Loo J, Schmiesing G (1965) Faktoren des fibrinolytischen Systems bei Leber-krankheiten. Thromb Diath Haemorrh 14: 580–591Google Scholar
  105. 104.
    Lorenz R (1986) Heparin bei akuter und chronischer Lebererkrankung (Kommentar). Leber Magen Darm 16: 122–125Google Scholar
  106. 105.
    Mannucci L, Dioguardi N, del Ninno E, Mannucci PM (1973) Value of normotest and antithrombin III in the assessment of liver function. Scand J Gastroenterol 8 [Suppl 19]: 103 — 107Google Scholar
  107. 106.
    Marciniak E, Gockerman JP (1977) Heparin-induced decrease in circulating anti- thrombin-III. Lancet 11: 581–584Google Scholar
  108. 107.
    Marongiu F, Mamusa AM, Mameli G, Mulas G, Solinas A, Demelia L, Contu L (1985) Alpha2-antiplasmin and fibrinopeptide A in liver cirrhosis (abstract) Haemostasis 14: 110Google Scholar
  109. 108.
    Martinez J, Palascak JE (1982) Hemostatic alterations in liver disease. In: Zakin D, Boyer TD (eds) Hepatology. A textbook of liver disease. Saunders, Philadelphia, pp 546–579Google Scholar
  110. 109.
    Matthias FR (1982) Umsatzstörungen im Gerinnungs- und Fibrinolyse-System durch Erkrankungen der Leber. Schwerpunktmed 5: 21 - 27Google Scholar
  111. 110.
    Matti R, Ambrus JL, Sokal IE, Mink E (1964) Production of members of the Blood coagulation and fibrinolysis systems by the isolated perfused liver. Proc Soc Exp Biol Med 116: 69–72Google Scholar
  112. 111.
    McAvoy TT (1979) The biological half-life of heparin. Clin Pharmacol Ther 25:372– 379Google Scholar
  113. 112.
    Mowat NAG, Brunt PW, Ogston D (1974) The fibrinolytic enzyme system in acute and chronic liver injury. Actat Haematol (Basel) 52: 289–293Google Scholar
  114. 113.
    Nanji AA, Blank DW (1983) Clinical status as reflected in biochemical tests on patients with chronic alcoholic liver disease. Clin Chem 29: 992–993PubMedGoogle Scholar
  115. 114.
    Neidhardt B, Schricker K Th (1982) Hämostasestörungen bei Leberzirrhose. Teil 2: Therapie. Fortschr Med 100: 836–840Google Scholar
  116. 115.
    Oehler G, Bleyl H, Bischoff B, Henk R (1974) Vergleich von Prothrombin-Aktivität und —Konzentration bei verschiedenen Funktionszuständen der Leber. Verh Dtsch Ges Inn Med 80: 1452–1456PubMedGoogle Scholar
  117. 116.
    Oehler G, Heckers H (1985) Hämostase bei gestörter Leberfunktion. Haemostaseologie 5: 75–81Google Scholar
  118. 117.
    Oehler G, Lasch HG (1984) Gerinnungsstörungen im Schock. In: Riecker G (Hrsg) Schock. Springer, Berlin-Heidelberg-New York (Handbuch der Inneren Medizin Bd IX 12., S 203 )Google Scholar
  119. 118.
    Ogston D, Bennett NB, Ogston CM (1971) The fibrinolytic enzyme system in hepatic cirrhosis and malignant metastases. J Clin Pathol 24: 822–826PubMedGoogle Scholar
  120. 119.
    Ogston D, Ogston CM, Ratnoff OD (1969) Studies on a complex mechanism for the activation of plasminogen by kaolin and by chloroform: the participation of Hagemann factor and additional factors. J Clin Invest 1786–1801Google Scholar
  121. 120.
    Oka K, Tanaka K (1979) Local fibrinolysis of esophagus and stomach as a cause of hemorrhage in liver cirrhosis. Thromb Res 14: 837–844PubMedGoogle Scholar
  122. 121.
    Olson JP, Miller LL, Troup SB (1966) Synthesis of clotting factors. J Clin Invest 45: 690–701PubMedGoogle Scholar
  123. 122.
    Olsson P, Lagergreen H, Ek S (1963) The elimination from plasma of intravenous heparin. Acta Med Scand 173: 619–630PubMedGoogle Scholar
  124. 123.
    Ordinas A, Maragall S, Castillo R, Nurden AT (1978) A glycoprotein I defect in platelets of three patients with severe cirrhosis of the liver. Thromb Res 13: 297–302PubMedGoogle Scholar
  125. 124.
    Owen CA, Bowie EJW (1981) Generation of plasmatic coagulation factors by the isolated rat live perfused with completely synthetic Blood substitute. Thromb Res 22: 259–266PubMedGoogle Scholar
  126. 125.
    Owens RM, Miller LL (1980) Net biosynthesis of antithrombin III by the isolated liver perfused for 12–24 hours. Biochim Biophys Acta 627: 30–39PubMedGoogle Scholar
  127. 126.
    Pabinger-Fasching J (1984) Protein C — ein in der Leber gebildeter Gerinnungsinhibitor. Haemostaseologie 4: 50–53Google Scholar
  128. 127.
    Pakter RL, Rüssel TR, Meilke CH, West D (1982) Coagulopathy associated with the use of moxalactam. JAMA 248: 1100PubMedGoogle Scholar
  129. 128.
    Palascak JE, Martinez J (1977) Dysfibrinogenemia associated with liver disease. J Clin Invest 60: 89–95PubMedGoogle Scholar
  130. 129.
    Permin PM (1950) The fibrinolytic activator in animal tissue. Acta Physiol Scand 21: 159–167PubMedGoogle Scholar
  131. 130.
    Phillips LL, Rodgers JB (1979) Procoagulant activity of ascitic fluid in hepatic cirrhosis. Surgery 86: 714–721PubMedGoogle Scholar
  132. 131.
    Poller L (1977) Coagulation abnormalities in liver disease. In: Poller L (ed) Recent advances in Blood coagulation, vol 2. Churchill Livingstone, Edinburgh, pp 267–292Google Scholar
  133. 132.
    Popov S (1973) Therapeutische Probleme (Diskussion). Thromb Diath Haemorrh [Suppl] 55: 153–159Google Scholar
  134. 133.
    Popper H, Franklin M (1948) Viral versus toxic hepatic necrosis. Arch Pathol 46:338– 376Google Scholar
  135. 134.
    Potron G, Droulle C, N’Guyen P et al. (1984) Main problems in the treatment of bleeding in cirrhotic patients. In: Fondu P, Thijs O (eds) Haemostatic failure in liver disease. Nijhoff, Boston pp 127–154Google Scholar
  136. 135.
    Prowse CV, Douglas JG, Forrest JAH, Forsling ML (1980) Haemostatic effects of lysine vasopressin and triglycyl lysine vasopressin infusion in patients with cirrhosis. Eur J Clin Invest 10: 49–54PubMedGoogle Scholar
  137. 136.
    Ragni MU, Lewis JH, Spero JA, Hasiba U (1982) Bleeding and coagulation abnormalities in alcohol cirrhosis liver disease. Alcoholism: Clin Exp Res 6 (2): 267–274Google Scholar
  138. 137.
    Ratnoff OD (1982) Disordered hemostasis in hepatic disease. In: Schiff L, Schiff ER (eds) Diseases of the liver. Lippincott, Philadelphia, pp 237–258Google Scholar
  139. 138.
    Ritland S, Skrede S, Blomhoff JP, Gjone E (1973) Coagulation factors as indicators of protein synthesis in chronic liver disease. Scand J Gastroenterol 8 [Suppl 19]: 113– 117Google Scholar
  140. 139.
    Robbins KC (1982) The plasminogen-plasmin enzyme system. In: Colman RW, Hirsh J, Marder VJ, Salzman EW (eds) Hemostasis and thrombosis: basic principles and clinical practice. Lippincott, Philadelphia, pp 623–639Google Scholar
  141. 140.
    Rock WA (1984) Laboratory assessment of coagulation disorders in liver disease. Clin Lab Med 4: 419–442PubMedGoogle Scholar
  142. 141.
    Rodzynek JJ, Urbain D, Leutaud P, Wettendorff P, Delcourt A (1984) Antithrombin III, plasminogen and alpha2-antiplasmin in jaundice, clinical usefulness and prognostic significance. Gut 25: 1050–1056PubMedGoogle Scholar
  143. 142.
    Rosenberg RD (1975) Actions and interactions of antithrombin and heparin. N Engl J Med 292: 146–151PubMedGoogle Scholar
  144. 143.
    Rosenberg RD (1984) The heparin-antithrombin mechanism. Triangle 23: 43–48Google Scholar
  145. 144.
    Rubin M, Weston M, Langley P, White Y, Williams R (1979) Platelet functions in chronic liver disease. Relation to disease severity. Dig Dis Sci 24: 197–202Google Scholar
  146. 145.
    Ruiz F, Grainger SL, Hall RJC, Ingram JC, Pollard V, Swan AV (1982) Relation of simple clotting tests to clotting factor levels in liver disease. Clin Lab Haematol 4:247– 256Google Scholar
  147. 146.
    Samama M (1984) The significance of several coagulation tests in the evaluation of the, risk of bleeding. In: Fondu P, Thijs O (eds) Haemostatic failure in liver disease. Nijhoff, Boston, pp 81–91Google Scholar
  148. 147.
    Sauder D, Seaton TL, Johnston M, Hirsch J (1977) Changes in the coagulation status of patients undergoing autotransfusion of concentrated ascitic fluid as treatment of refractory ascites. Blood 50 [Suppl 1]: 267 (Abstract)Google Scholar
  149. 148.
    Scharf R, Schneider W, Heisig S, Schramm W (1983) Thrombozytopenie bei Leberzirrhose. Klin Wochenschr 61: 703–708PubMedGoogle Scholar
  150. 149.
    Scharf R, Schramm W, Heisig S, Schneider W (1982) Does chronic disseminated intravascular coagulation (DIC) cause thrombocytopenia in patients with stable liver cirrhosis? Haemostasis 12: 39Google Scholar
  151. 150.
    Schneider W, Scharf RE, Schramm W (1982) Thrombozyten und Lebererkrankungen. Verh Dtsch Ges Inn Med 88: 1336–1339Google Scholar
  152. 151.
    Schneider M, Schulz K, Teichmann W (1973) Zum Verhalten der Blutgerinnungsfaktoren bei Patienten mit Verschlußikterus. Z Innere Med 28: 403–407Google Scholar
  153. 152.
    Schuster HP, Prellwitz W, Schönborn H, Olberman M (1976) Blutgerinnungsstörungen als Mitursache massiver gastrointestinaler Blutungen bei Patienten mit Leberzirrhose. Med Welt 27: 1392–1394PubMedGoogle Scholar
  154. 153.
    Sette H, Hughes RD, Langley PD, Gimson AES, Williams R (1985) Heparin response and clearance in acute and chronic liver disease. Thromb Haemost 54: 591–594PubMedGoogle Scholar
  155. 154.
    Sharma P, McDonald G, Banaji M (1982) The risk of bleeding after percutaneous liver biopsy. Relation to platelet count. J Clin Gastroenterol 4: 451–453Google Scholar
  156. 155.
    Shaw E, Giddings JC, Peake JR, Bloom AL (1979) Synthesis of procoagulant factor VIII. Factor VIII related antigen and other coagulation factors by the isolated perfused rat liver. Br J Haematol 41: 585–596Google Scholar
  157. 156.
    Soria J, Soria C, Ryckewaert JJ, Samama M, Thomson JM, Poller L (1980) Study of acquired dysfibrinogenemia in liver dysfibrinogenemia in liver disease. Thromb Res 19: 29–41PubMedGoogle Scholar
  158. 157.
    Spaet TH (1962) Studies on the in vivo behaviour of Blood coagulation product I in rats. Thromb Diath Haemorrh 8: 276–285PubMedGoogle Scholar
  159. 158.
    Spector J, Corn M, Ticktin HE (1966) Effect of plasma transfusions on the prothrombin time and clotting factors in liver disease. N Engl J Med 275: 1032–1037PubMedGoogle Scholar
  160. 159.
    Stakeberg H (1974) Substrate incorporation into lipids and proteins in human liver slices. Acta Med Scand [Suppl] 561: 1–30Google Scholar
  161. 160.
    Stein SF, Harker LA (1982) Kinetic and functional studies of platelets, fibrinogen, and plasminogen in patients with hepatic cirrhosis. J Lab Clin Med 99: 217–230PubMedGoogle Scholar
  162. 161.
    Stenflo J, Ganrot PO (1972) Vitamin K an the biosynthesis of prothrombin: Identification and purification of a dicumarol-induced prothrombin from bovine plasma. J Biol Chem 247: 8167–8175Google Scholar
  163. 162.
    Straub PW (1977) Diffuse interavascular coagulation in liver disease? Semin Thromb Hemost 4: 29–39PubMedGoogle Scholar
  164. 163.
    Sundsmo JS, Fair DS (1983) Relationships among the complement, kinin, coagulation and fibrinolytic systems. Springer Semin Immunpathol 6: 231–258Google Scholar
  165. 164.
    Teien AN (1977) Heparin elimination in patients with liver cirrhosis. Thromb Haemost 38: 701–706PubMedGoogle Scholar
  166. 165.
    Tucker JS, Woolf JL, Boyes BE (1973) Coagulation studies in acute hepatic failure. Gut 14: 418PubMedGoogle Scholar
  167. 166.
    Tytgat G, Collen D, De Vreker R, Verstraete M (1968) Investigation on the fibrinolytic system in liver cirrhosis. Acta Haematol (Basel) 40: 265–274Google Scholar
  168. 167.
    Tytgat GN, Collen D, Verstraete M (1971) Metabolism of fibrinogen in cirrhosis of the liver. J Clin Invest 50: 1690–1701PubMedGoogle Scholar
  169. 168.
    Veitkamp J J, Kreuning J (1973) The diagnostic value of coagulation studies in chronic liver disease. Scand J Gastroenterol 8 [Suppl 19]: 93–95Google Scholar
  170. 169.
    Verstraete M, Vermylen J, Collen D (1974) Intravascular coagulation in liver disease. Ann Rev Med 25: 447–455PubMedGoogle Scholar
  171. 170.
    Vogel GE (1983) Early treatment with AT III in acute liver failure. Behring Inst Mitt 73: 79–93PubMedGoogle Scholar
  172. 171.
    Vogel GE, Komm Ch, Lorenz R, Bottermann P (1984) Das akute Leberversagen — neue therapeutische Aspekte. Intensivbehandlung 9: 60–66Google Scholar
  173. 172.
    Volk BA, Schölmerich J, Wilms H, Köttgen E, Witz G, Billmann P, Hoppe-Seyler P, Gerok W (1985) Peritoneo-venöser Shunt in der Aszitestherapie. Dtsch Med Wochenschr 110: 1685–1691PubMedGoogle Scholar
  174. 173.
    Walker JRA, Willner MA, Johnston CA, Rand PB, Neame J, Hirsh J (1983) Factors XI and XII are low in subjects with liver disease. Dig Dis Sci 28: 967–970PubMedGoogle Scholar
  175. 174.
    Van der Watt JA, Gomperts ED, Kew MC (1977) Hemostatic factors in primary hepatocellular cancer. Cancer 40:1593 –1603Google Scholar
  176. 175.
    Wessler S, Yin ET, Gaston LW, Nicol J (1967) A distinction between the role of precursor and activated forms of clotting factors in the genesis of stasis thrombi. Thromb Diath Haemorrh 18: 12–23PubMedGoogle Scholar
  177. 176.
    White GC, Roberts HR, Kingdon HS, Lundblad RL (1977) Prothrombin complex concentrates: potentially thrombogenic materials and clues to the mechanism of thrombosis in vivo. Blood 49: 159–170PubMedGoogle Scholar
  178. 177.
    Wintrobe M (1981) Clinical hematology. 8th edn Lea & Febiger, Philadelphia, p 581Google Scholar
  179. 178.
    Wion K, Kelly DA, Summerfield JAS, Tuddenham EGD, Lawn D (1985) Distribution of factor VIII mRNA and antigen in human liver and other tissues. Nature 317:726– 729PubMedGoogle Scholar
  180. 179.
    Zetterquist E, von Francken J (1963) Coagulation disturbances with manifest bleeding in extrahepatic portal hypertension and in liver cirrhosis. Preliminary results of heparin treatment. Acta Med Scand 173: 753–760Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • A. Jedrychowski

There are no affiliations available

Personalised recommendations